Associate Scientist, Imaging and Exploratory Research
- 500 Technology Square, Cambridge, MA 02139, USA
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth.
- Conduct rodent surgeries to develop and execute on in-vivo studies via multiple routes of administration in order to assess biodistribution for Codiak assets
- Execute on automated & manual histopathology staining of multiple markers across several disease indications to drive Codiak’s exosome platform towards the clinic
- Evaluate exosome pharmacology using quantitative in-vitro and ex-vivo radioligand binding techniques including tissue section autoradiography and homogenate binding to help formulate a deeper understanding of exosome biology
- Conduct biochemical methodologies to isolate and purify exosomes sourced from cell lines and mammalian tissues
- Ensure integrity and timely completion of experiment protocol, data package, and report
- BSc. degree in molecular biology, pharmacology, immunology, pathology, or related fields
- Relevant experience in methods related to physiology, pathology, biochemistry and/or pharmacology from academia/biopharmaceutical industry.
- Strong organizational and communication skills
- Familiarity with aseptic rodent surgical techniques and dosing via multiple routes of administration
- Competency in assay protocol development, optimization, and trouble-shooting for multimodal pathology, biochemistry and/or pharmacology techniques.
- Radioligand binding experience is desirable though not explicitly required
- Recent graduate or 2+ years of relevant work experience in biopharmaceutical industry
- Good GLP Laboratory experience and practice is required
- Work experience in one or more broadly defined techniques and areas such as physiology & rodent surgeries histopathology, radioligand binding, enzyme assays, tissue/cell preparation including but not restricted to ultracentrifugation, TLC, homogenization and spectrophotometric analysis.
Compensation & Benefits
Codiak provides competitive compensation and benefits package that support and reward the contributions of each member of the team.
Forward Engineering on Nature’s Messenger System
Recent discoveries have demonstrated that exosomes derived from normal cells can act as a potent and safe delivery system for multiple therapeutic payloads. These small vesicles, which leave cells and travel throughout the body, can mediate dramatic effects in animal models of disease.
We are developing a broad platform for the delivery of macromolecules to the cytoplasm of diverse cells and tissues, to create a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need. The company’s technology exploits the natural propensity of exosomes to transmit macromolecule payloads between cells to create a pipeline of drugs across a broad range of diseases, including those associated with currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas.
We are now producing drug candidate exosomes using the engExTM platform, our novel therapeutic engine for exosomes. We tailor exosomes to express molecules on their surfaces and/or deliver specific cargo inside. This affords us the flexibility for designing proprietary drug candidates; exosomes can be mixed and matched into rational and targeted combinations with the potential for a broad therapeutic platform.
As of December 2017, Codiak has raised a combined $168.5M in Series A-C financing. The company maintains partnerships with academic exosome labs and has multiple paths to clinical and commercial success through the breadth of the company’s research, strength of its IP position and proprietary innovation behind its production capabilities.
Inspired Employees Create Great Science
Codiak’s CEO and first employee Doug Williams, Ph.D., (former EVP of Biogen R&D, CEO of ZymoGenetics) espouses the belief that inspired employees create great science. Employees treat the company as if it was their own and report that there is “direct and respectful communication,” and “trust that teammates will do the right thing and never compromise integrity.”
Named one of 11 disruptive startups “on a do-or-die mission to launch new meds” by Endpoints News in January 2018, Codiak is in the heart of Boston’s biotechnology hub at 500 Technology Square in Cambridge, Massachusetts.
Codiak BioSciences is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.